Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant-Reference-Cited by-同舟云学术

Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant

Published:2017-04-06 Issue:14 Volume:129 Page:2033-2037
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Hiwarkar Prashant¹^ORCID,Amrolia Persis²,Sivaprakasam Ponni³,Lum Su Han⁴,Doss Hemalatha⁵,O’Rafferty Ciara¹,Petterson Toni⁶,Patrick Katharine⁷,Silva Juliana²,Slatter Mary⁵,Lawson Sarah¹,Rao Kanchan²,Steward Colin³,Gassas Adam³,Veys Paul²,Wynn Robert⁴

Affiliation:

1. Department of Haematology and Bone Marrow Transplantation, Birmingham Children’s Hospital, Birmingham, United Kingdom;

2. Department of Bone Marrow Transplantation, Great Ormond Street Hospital for Children, London, United Kingdom;

3. Department of Bone Marrow Transplantation, Royal Hospital for Children, Bristol, United Kingdom;

4. Department of Bone Marrow Transplantation, Royal Manchester Children’s Hospital, Manchester, United Kingdom;

5. Department of Bone Marrow Transplantation, Great North Children’s Hospital, Newcastle upon Tyne, United Kingdom;

6. Department of Bone Marrow Transplantation, Royal Marsden Hospital, Sutton, United Kingdom; and

7. Department of Bone Marrow Transplantation, Sheffield Children’s Hospital, Sheffield, United Kingdom

Abstract

Key Points Brincidofovir has superior antiadenoviral activity and safety profile compared with cidofovir. Brincidofovir is highly efficacious in controlling adenoviremia during the lymphopenic phase of HCT.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/14/2033/1399817/blood749721.pdf

Reference18 articles.

1. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients;Hiwarkar;Bone Marrow Transplant,2013

2. How I treat adenovirus in hematopoietic stem cell transplant recipients;Lindemans;Blood,2010

3. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study;Boeckh;Blood,1996

4. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation;Einsele;Blood,1995

5. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation;Worth;Br J Haematol,2011

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel derivatives of BCV and (S)-HPMPA inhibit orthopoxviruses and human adenoviruses more potently than BCV;2024-09-02

2. Pitfalls in definitions on respiratory viruses and particularities of Adenovirus infection in hematopoietic cell transplantation patients: Recommendations from the EBMT practice harmonization and guidelines committee;Current Research in Translational Medicine;2024-09

3. Structural basis of human mpox viral DNA replication inhibition by brincidofovir and cidofovir;International Journal of Biological Macromolecules;2024-06

4. SOHO State of the Art Updates and Next Questions | CTLs for Infections Following Stem Cell Transplantation;Clinical Lymphoma Myeloma and Leukemia;2024-06

5. On behalf of the SFGM‐TC: Real‐life use of third‐party virus‐specific T‐cell transfer in immunocompromised transplanted patients;HemaSphere;2024-01